1684 related articles for article (PubMed ID: 33602698)
1. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L
J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698
[TBL] [Abstract][Full Text] [Related]
2. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
3. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
[TBL] [Abstract][Full Text] [Related]
4. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.
Kurano M; Morita Y; Nakano Y; Yokoyama R; Shimura T; Qian C; Xia F; He F; Zheng L; Ohmiya H; Kishi Y; Okada J; Yoshikawa N; Nakajima K; Nagura Y; Okazaki H; Jubishi D; Moriya K; Seto Y; Yasui F; Kohara M; Wakui M; Kawamura T; Kodama T; Yatomi Y
Int Immunopharmacol; 2022 Feb; 103():108491. PubMed ID: 34954559
[TBL] [Abstract][Full Text] [Related]
5. A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.
Jalkanen P; Pasternack A; Maljanen S; Melén K; Kolehmainen P; Huttunen M; Lundberg R; Tripathi L; Khan H; Ritvos MA; Naves R; Haveri A; Österlund P; Kuivanen S; Jääskeläinen AJ; Kurkela S; Lappalainen M; Rantasärkkä K; Vuorinen T; Hytönen J; Waris M; Tauriainen S; Ritvos O; Kakkola L; Julkunen I
J Infect Dis; 2021 Jul; 224(2):218-228. PubMed ID: 33905505
[TBL] [Abstract][Full Text] [Related]
6. Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk.
Demers-Mathieu V; Do DM; Mathijssen GB; Sela DA; Seppo A; Järvinen KM; Medo E
J Perinatol; 2021 Apr; 41(4):850-859. PubMed ID: 32873904
[TBL] [Abstract][Full Text] [Related]
7. Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers.
Demers-Mathieu V; DaPra C; Mathijssen G; A Sela D; M Jarvinen K; Seppo A; Fels S; Medo E
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572480
[TBL] [Abstract][Full Text] [Related]
8. Performance of nucleocapsid and spike-based SARS-CoV-2 serologic assays.
Rikhtegaran Tehrani Z; Saadat S; Saleh E; Ouyang X; Constantine N; DeVico AL; Harris AD; Lewis GK; Kottilil S; Sajadi MM
PLoS One; 2020; 15(11):e0237828. PubMed ID: 33137138
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera.
Ha B; Jadhao S; Hussaini L; Gibson T; Stephens K; Salazar L; Ciric C; Taylor M; Rouphael N; Edupuganti S; Rostad CA; Tompkins SM; Anderson EJ; Anderson LJ
Microbiol Spectr; 2021 Oct; 9(2):e0045821. PubMed ID: 34494855
[TBL] [Abstract][Full Text] [Related]
10. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population.
Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R
Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691
[TBL] [Abstract][Full Text] [Related]
11. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.
Nguyen-Contant P; Embong AK; Kanagaiah P; Chaves FA; Yang H; Branche AR; Topham DJ; Sangster MY
mBio; 2020 Sep; 11(5):. PubMed ID: 32978311
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients.
Sun B; Feng Y; Mo X; Zheng P; Wang Q; Li P; Peng P; Liu X; Chen Z; Huang H; Zhang F; Luo W; Niu X; Hu P; Wang L; Peng H; Huang Z; Feng L; Li F; Zhang F; Li F; Zhong N; Chen L
Emerg Microbes Infect; 2020 Dec; 9(1):940-948. PubMed ID: 32357808
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal detection of SARS-CoV-2-specific antibody responses with different serological methods.
Emmerich P; von Possel R; Hemmer CJ; Fritzsche C; Geerdes-Fenge H; Menge B; Messing C; Borchardt-Lohölter V; Deschermeier C; Steinhagen K
J Med Virol; 2021 Oct; 93(10):5816-5824. PubMed ID: 34061367
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins.
Favresse J; Cadrobbi J; Eucher C; Elsen M; Laffineur K; Dogné JM; Douxfils J
J Med Virol; 2021 Apr; 93(4):2262-2269. PubMed ID: 33200836
[TBL] [Abstract][Full Text] [Related]
15. Humoral response to spike S1 and S2 and nucleocapsid proteins on microarray after SARS-CoV-2 infection.
Portilho AI; Silva VO; Ahagon CM; Matsuda EM; de Oliveira EL; da Silveira EPR; de Souza Lima AK; Lindoso JAL; de Campos IB; Hong MA; De Gaspari E; de Macedo Brígido LF
J Med Virol; 2022 Jan; 94(1):178-185. PubMed ID: 34428312
[TBL] [Abstract][Full Text] [Related]
16. Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin.
Emmerich P; Murawski C; Ehmen C; von Possel R; Pekarek N; Oestereich L; Duraffour S; Pahlmann M; Struck N; Eibach D; Krumkamp R; Amuasi J; Maiga-Ascofaré O; Rakotozandrindrainy R; Asogun D; Ighodalo Y; Kann S; May J; Tannich E; Deschermeier C
Trop Med Int Health; 2021 Jun; 26(6):621-631. PubMed ID: 33666297
[TBL] [Abstract][Full Text] [Related]
17. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients.
Chansaenroj J; Yorsaeng R; Posuwan N; Puenpa J; Sudhinaraset N; Chirathaworn C; Poovorawan Y
Virol J; 2021 Mar; 18(1):52. PubMed ID: 33750394
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections.
Huber T; Steininger P; Irrgang P; Korn K; Tenbusch M; Diesch K; Achenbach S; Kremer AE; Werblow M; Vetter M; Bogdan C; Held J
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1983-1997. PubMed ID: 34109500
[TBL] [Abstract][Full Text] [Related]
19. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
[TBL] [Abstract][Full Text] [Related]
20. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies.
Tré-Hardy M; Wilmet A; Beukinga I; Favresse J; Dogné JM; Douxfils J; Blairon L
J Med Virol; 2021 Feb; 93(2):803-811. PubMed ID: 32667733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
